Voyager Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.44.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.86.
During the past 3 years, the average EBIT per Share Growth Rate was -19.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Voyager Therapeutics's EBIT per Share or its related term are showing as below:
FRA:VT6'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40 Med: 6.85 Max: 55.2
Current: -19.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Voyager Therapeutics was 55.20% per year. The lowest was -40.00% per year. And the median was 6.85% per year.
FRA:VT6's 3-Year EBIT Growth Rate is ranked worse than 86.51% of 1179
companies
in the Biotechnology industry
Industry Median: 15.6
vs FRA:VT6: -19.20
Voyager Therapeutics (FRA:VT6) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Voyager Therapeutics EBIT per Share Related Terms
Voyager Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (FRA:VT6) has a EBIT per Share of €-1.86 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #1020 out of 1179 companies in the Biotechnology industry, placing it in the top 86.5%.
Is Voyager Therapeutics' EBIT per Share too high?
Voyager Therapeutics' current EBIT per Share is €-1.86. Based on the distribution chart, Voyager Therapeutics ranks #1020 out of 1179 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Voyager Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' EBIT per Share compare to KROS and CDXS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #1020 out of 1179 companies for EBIT per Share. This places Voyager Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.60, based on 1,179 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Voyager Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current EBIT per Share is €-1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.38, compared to a current price of €2.91 — trading 111% above its estimated fair value. The current EBIT per Share is €-1.86. Voyager Therapeutics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current EBIT per Share is €-1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.91 is trading 111% above its estimated GF Value™ of €1.38.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
EBIT per Share: €-1.86
GF Value™: €1.38 vs. price of €2.91 (111% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
53GF Score
Get the complete analysis for FRA:VT6
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
